Prelude Therapeutics Inc (PRLD NASDAQ) stock market data APIs
$3.5957
-0.12(-3.3%)
as of November 6, 2026
Try our APIs with
free plan!
Prelude Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Prev. Close
3.5957
Open
3.471
High
3.7116
Low
3.3215
52 wk Range
1.173-6.83
Market Cap
287 M
Shares Outstanding
65 075 K
Revenue
22 424 K
Beta
1.19
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Prelude Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Prelude Therapeutics Inc data using free add-ons & libraries
Get Prelude Therapeutics Inc Fundamental Data
Prelude Therapeutics Inc Fundamental data includes:
- Net Revenue: 22 424 K
- EBITDA: -64 510 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Prelude Therapeutics Inc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-11-11
- EPS/Forecast: -0.14
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Prelude Therapeutics Inc News
New
Earnings Preview: Merck KGaA (MKKGY) Q3 Earnings Expected to Decline
Merck KGaA (MKKGY) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook gives...
Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?
Hospital operator Tenet Healthcare Corporation THC is set to report third-quarter 2026 results on Oct. 29, 2026, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter's ...
Eli Lilly (LLY) Reported One Year Steroid Free Control In Difficult IBD
Eli Lilly (NYSE: LLY) reported new clinical analyses showing its Omvoh therapy achieved corticosteroid free disease control at one year in ulcerative colitis and Crohn's disease. The data include pati...
Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer
Prelude Therapeutics, Incorporated Combination cohorts are part of Prelude's Phase 1 trial evaluating PRT13722 in patients with HR+/HER2- breast cancer, on track to initiate enrollment in the fourth ...
Get Prelude Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.